var data={"title":"Tetanus immune globulin (human): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tetanus immune globulin (human): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7028?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tetanus-immune-globulin-human-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tetanus immune globulin (human): Patient drug information&quot;</a> and <a href=\"topic.htm?path=tetanus-immune-globulin-human-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Tetanus immune globulin (human): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226065\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>HyperTET S/D</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226066\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>HyperTET S/D</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226076\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Blood Product Derivative;</li>\n      <li>\n        Immune Globulin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226067\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tetanus, prophylaxis:</b> IM: 250 units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Tetanus, treatment:</b> IM: 3,000 to 6,000 units. Infiltration of part of the dose around the wound is recommended (MMWR 2015; <i>Red Book </i>[AAP 2015]). Some experts recommend a lower 500 unit dose which appears to be as effective as higher doses and may cause less discomfort (<i>Red Book</i> [AAP 2015]; WHO 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Tetanus prophylaxis in wound management:</b> IM: Tetanus prophylaxis in patients with wounds should based on if the wound is clean or contaminated and the immunization status of the patient. Would management includes proper use of tetanus toxoid and/or tetanus immune globulin (TIG), wound cleaning, and (if required) surgical debridement and the proper use of antibiotics. Patients with an uncertain or incomplete tetanus immunization status should have additional follow up to ensure a series is completed. Patients with a history of Arthus reaction following a previous dose of a tetanus toxoid-containing vaccine should not receive a tetanus toxoid-containing vaccine until &gt;10 years after the most recent dose even if they have a wound that is neither clean nor minor. See table.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Tetanus Prophylaxis in Wound Management</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">History of Tetanus Immunization Doses</p></th>\n          <th colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Clean, Minor Wounds</p></th>\n          <th colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">All Other Wounds<sup>1</sup></p></th></tr>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Tetanus Toxoid<sup>2</sup></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">TIG</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Tetanus Toxoid<sup>2</sup></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">TIG</p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"5\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>1</sup>Such as, but not limited to, wounds contaminated with dirt, feces, soil, and saliva; puncture wounds; wounds from crushing, tears, burns, and frostbite. </p></td></tr>\n        <tr>\n          <td colspan=\"5\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>2</sup>Tetanus toxoid in this chart refers to a tetanus toxoid-containing vaccine. For children &lt;7 years of age, DTaP (DT, if pertussis vaccine contraindicated) is preferred to tetanus toxoid alone. For children &ge;7 years and Adults, Td preferred to tetanus toxoid alone; Tdap may be preferred if the patient has not previously been vaccinated with Tdap.</p></td></tr>\n        <tr>\n          <td colspan=\"5\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>3</sup>Yes, if &ge;10 years since last dose.</p></td></tr>\n        <tr>\n          <td colspan=\"5\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>4</sup>Yes, if &ge;5 years since last dose.</p></td></tr>\n        <tr>\n          <td colspan=\"5\" align=\"left\">\n            <p style=\"text-indent:0em;\">Adapted from CDC &quot;Pink Book,&quot; &quot; Epidemiology and Prevention of Vaccine-Preventable Diseases, Tetanus&quot; (available at <a target=\"_blank\" href=\"http://www.cdc.gov/vaccines/pubs/pinkbook/index.html&amp;token=mjmpv7xMHRIW2nr+3NCnsTubP6YtVyki9h+Z03HFKkAg7dcVwGjOdgSzWip0rCjNkUk9Ta3xUGHFRsPkWXRbyw==&amp;TOPIC_ID=9983\" target=\"_blank\">http://www.cdc.gov/vaccines/pubs/pinkbook/index.html</a>) and <i>MMWR</i> 2006, 55(RR-17).</p></td></tr>\n        <tr>\n          <td colspan=\"5\" valign=\"top\" align=\"left\">\n            <p style=\"text-indent:0em;\">Abbreviations: <b>DT</b> = Diphtheria and Tetanus Toxoids (formulation for age &le;6 years); <b>DTaP</b> = Diphtheria and Tetanus Toxoids, and Acellular Pertussis (formulation for age &le;6 years; Daptacel, Infanrix); <b>Td</b> = Diphtheria and Tetanus Toxoids (formulation for age &ge;7 years; Decavac,Tenivac); <b>TT</b>= Tetanus toxoid (adsorbed [formulation for age &ge;7 years]); <b>Tdap</b> = Diphtheria and Tetanus Toxoids, and Acellular Pertussis (Adacel or Boostrix [formulations for age &ge;7 years]); <b>TIG</b> = Tetanus Immune Globulin</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Uncertain or &lt;3 doses</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Yes</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">No</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Yes</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Yes</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>3 or more doses</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">No<sup>3</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">No</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">No<sup>4</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">No</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226072\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=tetanus-immune-globulin-human-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Tetanus immune globulin (human): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tetanus, prophylaxis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children &lt;7 years: IM: 4 units/kg; some recommend administering 250 units (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &ge;7 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tetanus, treatment:</b> Refer to adult dosing. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tetanus prophylaxis in wound management:</b> Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226068\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22803244\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22803245\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226053\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injectable, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HyperTET S/D: 250 units/mL (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226040\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226056\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IM: For IM use only; do not administer IV. Administer in the anterolateral aspects of the upper thigh or the deltoid muscle of the upper arm. Avoid gluteal region due to risk of injury to sciatic nerve; if gluteal region is used, administer only in the upper outer quadrant. If tetanus vaccine and tetanus immune globulin are administered simultaneously, separate sites should be used for each injection. When used for the treatment of tetanus, infiltration of part of the dose around the wound is recommended (MMWR 2015; <i>Red Book</i> [AAP 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226054\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tetanus prophylaxis:</b> For prophylaxis against tetanus following injury in patients whose immunization is incomplete or uncertain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tetanus treatment:</b> Treatment of active tetanus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">The Advisory Committee on Immunization Practices (ACIP) recommends passive immunization with TIG for the following:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persons with a wound that is not clean or minor and who have received &le;2 or an unknown number of adsorbed tetanus toxoid doses (CDC 55[RR3] 2006; CDC 55[RR17] 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persons who are wounded in bombings or similar mass casualty events if no reliable history of completed primary vaccination with tetanus exists. In case of shortage, use should be reserved for persons &ge;60 years of age and immigrants from regions other than Europe or North America (CDC 57[RR6] 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226047\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Increased body temperature</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Local soreness/soreness at injection site, pain at injection site, tenderness at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylactic shock, angioedema, nephrotic syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25709161\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226044\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions can occur; immediate treatment (including epinephrine 1 mg/mL) should be available. Use with caution in patients with isolated immunoglobulin A deficiency or a history of systemic hypersensitivity to human immunoglobulins.  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bleeding disorders: Use with caution in patients with thrombocytopenia or coagulation disorders; IM injections may be contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Administration: Not for intravenous administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: When used for the treatment of tetanus infection, TIG removes circulating toxin, but does not remove toxin bound to nerve endings (CDC 2012). Larger doses of TIG are needed for treatment than prophylaxis (see Dosage) (MMWR 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Skin testing: Skin testing should not be performed as local irritation can occur and be misinterpreted as a positive allergic reaction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300119\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226048\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9983&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immune Globulins may diminish the therapeutic effect of Vaccines (Live).  Management: Consult full interaction monograph for dose interval recommendations.  This interaction does not apply to oral Ty21a typhoid vaccine or others listed as exceptions.<b> Exceptions: </b>Influenza Virus Vaccine (Live/Attenuated); Rotavirus Vaccine; Yellow Fever Vaccine; Zoster Vaccine (Live/Attenuated).<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226050\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6742397\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Tetanus immune globulin and a tetanus toxoid containing vaccine are recommended by the ACIP as part of the standard wound management to prevent tetanus in pregnant women (CDC 57[RR6], 2008; CDC 62[7], 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226043\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Provides passive immunity towards tetanus by supplying antibodies to neutralize the free form of toxins produced by <i>Clostridium tetani</i>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226058\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Individuals with normal IgG concentration: ~23 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: IgG concentration: IM: ~2 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323952\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Injection</b> (HyperTET S/D Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 units/mL (1): $597.64</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226061\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>BayTet (MX, PK);</li>\n      <li>Hyper-Tet (HK, KR);</li>\n      <li>Hypertet (IL, TW);</li>\n      <li>Igantet (AR, CL, MY, SG);</li>\n      <li>Ronsen Yipu (CN);</li>\n      <li>Sero-Tet (MY, PH);</li>\n      <li>Tetabulin (AT, CZ, IT, KR, PL);</li>\n      <li>Tetabulin S/D (AR);</li>\n      <li>Tetabuline (BE);</li>\n      <li>Tetagam (AT, CH, IE, PT, ZA);</li>\n      <li>Tetagam P (DE, HK, ID, PH);</li>\n      <li>Tetagam-P (GR, LK, TH);</li>\n      <li>Tetaglobulin (IN);</li>\n      <li>Tetaglobuline (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Tetanobulin (TW);</li>\n      <li>Tetanobulin S/D (DE);</li>\n      <li>Tetanogamma (BR, DO);</li>\n      <li>Tetanogamma P (MX);</li>\n      <li>Tetgam (LB);</li>\n      <li>Tetuman (NL);</li>\n      <li>Tetuman berna (HK, PE, TH, TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control, &ldquo;Recommendations for Postexposure Interventions to Prevent Infection With Hepatitis B Virus, Hepatitis C Virus, or Human  Immunodeficiency Virus, and Tetanus in Persons Wounded During Bombings and Other Mass-Casualty Events -- United States, 2008: Recommendations of the Centers For Disease Control And Prevention (CDC),&rdquo; <i>MMWR Recomm Rep</i>, 2008, 57(RR-6):1-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetanus-immune-globulin-human-drug-information/abstract-text/18668022/pubmed\" target=\"_blank\" id=\"18668022\">18668022</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a></a>Centers for Disease Control. Preventing Tetanus, Diphtheria, and Pertussis Among Adolescents:  Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2006; 55(RR-3).</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a></a>Centers for Disease Control. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. <i>MMWR Recomm Rep</i>. 2006;55(RR-17):1-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetanus-immune-globulin-human-drug-information/abstract-text/17167397/pubmed\" target=\"_blank\" id=\"17167397\">17167397</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a></a>Centers for Disease Control and Prevention. <i>Epidemiology and Prevention of Vaccine-Preventable Diseases</i>. Atkinson W, Wolfe S, Hamborsky J, eds.12th ed., second printing. Washington DC: Public Health Foundation, 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Missed opportunities for tetanus postexposure prophylaxis &ndash; California, January 2008 &ndash; March 2014. <i>MMWR. Morb Mortal Wkly Rep</i>. 2015; 64(9)243-246.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetanus-immune-globulin-human-drug-information/abstract-text/25763876/pubmed\" target=\"_blank\" id=\"25763876\">25763876</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a></a>Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women--Advisory Committee on Immunization Practices (ACIP), 2012. <i>MMWR Morb Mortal Wkly Rep</i>. 2013;62(7):131-135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetanus-immune-globulin-human-drug-information/abstract-text/23425962/pubmed\" target=\"_blank\" id=\"23425962\">23425962</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo; <i>Am J Health-Syst Pharm</i>, 2007, 64(16):1711-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetanus-immune-globulin-human-drug-information/abstract-text/17687059/pubmed\" target=\"_blank\" id=\"17687059\">17687059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a></a>HyperTET S/D (tetanus immune globulin [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics; September 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization, WHO Technical Note. Current recommendations for the treatment of tetanus during humanitarian emergencies. January 2010. Available at: http://www.who.int/diseasecontrol_emergencies/who_hse_gar_dce_2010_en.pdf.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9983 Version 89.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F226065\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F226066\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F226076\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F226067\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F226072\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F226068\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22803244\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22803245\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F226053\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F226040\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F226056\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F226054\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F226047\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F25709161\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F226044\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300119\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F226048\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F226050\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6742397\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F226043\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F226058\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323952\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F226061\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9983|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tetanus-immune-globulin-human-patient-drug-information\" class=\"drug drug_patient\">Tetanus immune globulin (human): Patient drug information</a></li><li><a href=\"topic.htm?path=tetanus-immune-globulin-human-pediatric-drug-information\" class=\"drug drug_pediatric\">Tetanus immune globulin (human): Pediatric drug information</a></li></ul></div></div>","javascript":null}